Overview of Quimbo

Property	Description
Active ingredient	Levodropropizine
Form	Tablet, Syrup, Oral solution, Drops
Pharmacological class	Peripheral Antitussive Agent
Common use	Symptomatic treatment of non-productive (dry) cough
Origin	Synthetic, Non-opioid

Quimbo is a trade name for the active pharmacological substance Levodropropizine, which is classified as a peripheral antitussive agent used for cough suppression. This medicinal entity is a synthetic molecule, derived as the levo isomer of the compound dropropizine. As a peripheral antitussive, Levodropropizine operates by acting directly on the nerve endings in the airways, a mechanism that distinguishes it from centrally acting cough suppressants which modify the cough reflex center in the brain. Pharmacological studies suggest this medicine provides clinically recognized relief by reducing cough intensity and nocturnal awakenings.

Composition, Origin, and Available Forms

The medication is supplied as a single-ingredient product, containing only the active substance Levodropropizine. The compound is inherently a non-opioid and non-narcotic agent, a safety profile that is crucial in distinguishing it from older narcotic-based antitussives. For oral administration, Quimbo is available in several high-level pharmaceutical preparations, including tablets, syrup, and an oral solution or drops, allowing for flexible delivery tailored to patient needs. The rapid absorption after oral use is noted in pharmacokinetic analysis.

General Purpose: How Quimbo Relieves Cough Symptoms

The primary purpose of Quimbo is the symptomatic treatment of cough, specifically aimed at providing relief from the irritating, non-productive cough (dry cough). This therapeutic benefit is achieved through its peripherally acting mechanism, which involves reducing the excitability of the sensory nerve fibers in the tracheobronchial tree that generate the cough signal. By mitigating this sensory overstimulation locally in the respiratory tract, the medicine effectively lowers the frequency and intensity of the involuntary urge to cough without interfering with essential respiratory functions.

What side effects are possible with Quimbo?

Possible Side Effects and Safety Information for Quimbo

This section outlines the officially documented adverse reactions and safety constraints for Quimbo, strictly as defined in government regulatory labeling.

Adverse Reaction Scope

Adverse reactions are classified by their documented frequency of occurrence and the major body systems affected (System-Organ-Class or SOC). This helps in understanding the likelihood of experiencing certain effects.

Classification	Example Adverse Reactions (Based on Regulatory Data)
Very Common (≥ 1/10)	Pruritus, Nausea, Vomiting
Common (≥ 1/100 to < 1/10)	Fatigue, Headache
Serious Adverse Reactions	Pulmonary Embolism (reported incidence 1%), Tumour Haemorrhage, Severe Cerebral Oedema (reported within 2 weeks to 6 months of starting therapy).

Key Safety Constraints and Warnings

System-Organ Classes Involved: Adverse effects have been documented across Gastrointestinal disorders, Nervous system disorders, Blood and lymphatic system disorders, and Skin and subcutaneous tissue disorders.
Population-Specific Restrictions: Quimbo is contraindicated in patients with decompensated cirrhosis or a prior decompensation event (e.g., Child-Pugh Class B or C). Specific safety recommendations are provided for use during pregnancy and lactation in official labeling.
Monitoring Requirements: Liver function monitoring is recommended due to the potential risk of hepatobiliary adverse reactions. Appropriate medical support must be readily available during administration due to the risk of hypersensitivity.
Time-Related Patterns: Some side effects, such as Pruritus and Flu-like Syndrome, are often reported to be most prominent during the initiation of therapy and may decrease over time with continued use.

Overdose and Emergency Response

The regulatory overdose profile for Quimbo (Levodropropizine) is based on the documented manifestations and mandated emergency response. Officially described overdose presentations are typically non-severe, characterized by a temporary transitional tachycardia (increased heart rate). Isolated cases, including a report in a pediatric patient, have also shown transient gastrointestinal effects such as abdominal pain, nausea, and vomiting.

Given that no specific antidote is available for the treatment of an overdose, management is focused entirely on symptomatic and supportive therapies. When an overdose is suspected or evident clinical signs are present, it is required to seek immediate medical attention to set up symptomatic therapy and adopt the usual emergency measures. These procedures, as detailed in regulatory documents, include steps such as the use of gastric lavage and activated charcoal.

During supportive care, special attention is required for the patient’s major physiological functions. This includes monitoring cardiac, respiratory, renal, and hepatic functions, in addition to observing fluid and electrolytic balance. This rigorous monitoring, combined with general supportive care, defines the officially mandated approach to managing over-exposure to the medicine.

Therapeutic Uses of Quimbo

What Quimbo treats: Main Uses and Benefits

The medication is used within the therapeutic domain of antitussives, which generally focuses on the symptomatic relief of dry cough. This approach is consistent with common regulatory and clinical guidance.

Symptomatic Relief of the Irritating Dry Cough

Quimbo is commonly used to help with symptoms related to inflammatory or irritative states in the airways, specifically addressing the dry, hacking, non-productive cough. It provides support that helps ease the overall symptom burden of the persistent cough, and may assist with managing symptoms that create noticeable physiological strain, leading to reduced intensity and frequency of the cough.

Therapeutic Support in Acute Respiratory Conditions

This medication is relevant for easing symptoms associated with acute or disruptive episodes, such as those that may accompany upper respiratory infections or bronchitis. It is applied in contexts where additional symptomatic support is needed during phases when symptoms become more noticeable, particularly for the lingering, post-infectious cough component.

Mitigating Disruption to Sleep and Daily Functioning

Quimbo supports the patient during difficult episodes by easing distress and is used when groups of symptoms interfere with daily comfort, particularly nocturnal coughing. This contributes to easing the overall symptom load, which supports improved day-to-day comfort and assists with maintaining functional stability during symptomatic phases. The medicine is relevant for easing symptomatic manifestations, including the irritative dry cough, cough associated with acute respiratory infections, and nocturnal cough disruption.

Quick Fact: Relief for Disruptive Cough Quimbo contributes to easing the overall symptom load, which supports improved day-to-day comfort and assists with maintaining functional stability by suppressing the persistent, non-productive cough.

Regulatory References

Health Canada Guidance on Antitussive Labeling

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quimbo — Official Regulatory Information

The eligibility for Quimbo (Levodropropizine) is determined by governmental regulatory documents that classify populations as either approved, restricted, or absolutely contraindicated based on age, physiological status, and underlying conditions.

Eligibility Scope	Regulatory Status	Details (Official Labeling)
Contraindicated Populations	Must not use	Known hypersensitivity to the medicine, severe hepatic (liver) impairment, bronchorrhea (excessive bronchial secretion), and conditions with reduced mucociliary function (e.g., Kartagener's Syndrome) [1.2, 1.3].
Age-Related Rules	Approved / Not Established	Approved for adults and children aged 2 years and older. Contraindicated or not recommended for children under 2 years of age as safety and efficacy are not established [1.3, 1.7].
Maternal Status	Contraindicated	Pregnancy and lactation (breastfeeding) are contraindicated due to insufficient clinical data regarding potential toxicity [1.3].
Organ Function Restrictions	Caution Recommended	Caution is required in patients with severe renal (kidney) impairment (creatinine clearance < 35 mL/min) and in older adults [1.3, 1.7].

The official eligibility profile sets absolute prohibitions against groups with specific physiological or clinical conditions and for life stages where safety data is lacking [1.3]. For other populations, such as older adults, the status shifts to conditional use, indicating that eligibility may require monitoring or caution as defined by the regulatory label [1.7]. This framework strictly dictates the permitted population for the medicine under standard label conditions.

What should I know about interactions with other medicines?

The official interaction profile for Quimbo (Levodropropizine) is based on two primary regulatory constraints: pharmacodynamic risk and administration timing rules.

Pharmacodynamic and Drug–Drug Interactions

The primary documented interaction is categorized as pharmacodynamic reinforcement. Official labeling advises caution when co-administering with sedative drugs, including hypnotics and sedating antihistamines, especially in sensitive individuals. This constraint is due to the potential for an additive sedative effect, which may increase the risk of symptoms like drowsiness. While clinical trials did not observe interactions with benzodiazepines specifically, the general warning for the sedative class remains.

Regulatory documentation confirms that clinical studies did not reveal interactions following simultaneous administration of common bronchopulmonary medicines, such as beta2-agonists, methylxanthines, or corticosteroids. Furthermore, animal pharmacology studies have indicated that the medicine does not potentiate the pharmacological effect of alcohol.

Administration Timing and Population Notes

A label-based timing constraint is required for administration. Since the effect of concomitant food intake on the drug’s absorption is not definitively determined, it is officially advised to take the medicine away from meals or between meals.

Official notes advise caution when administering to elderly patients, citing a potential for changed pharmacokinetics linked to age. No specific CYP-mediated or transporter-based interactions are documented in the official prescribing information.

Mechanism of Action

Peripheral Inhibition of Vagal Sensory Signaling

The primary mechanism of action involves the localized desensitization and blockade of vagal afferent C-fibers , which are the sensory nerve endings responsible for generating nerve impulses in the airways. By stabilizing the membrane potential of these sensory nerves, Levodropropizine reduces their excitability, functionally preventing them from initiating an excessive impulse in response to local irritants. This targeted, peripheral action reduces the transmission of the afferent impulse in the reflex arc.

⬇️ Modulation of the Afferent Cough Reflex Cascade

The molecular action of reducing C-fiber excitability initiates a clear physiological cascade: fewer impulses are transmitted to the central cough center in the brainstem. This results in a decrease in the magnitude of the afferent signal to the central nervous system, as the central system receives a lower frequency of afferent impulses. This action does not impair mucociliary clearance. The mechanism is distinct from pathways influencing central respiratory drive. An ancillary mechanism involves minor modulation of H1 receptors, which contributes to a decrease in local sensory stimulation.

Dosage and Administration Information

Administration and Official Usage Guidelines

Quimbo, which contains Levodropropizine, is administered strictly via the oral route using available preparations: tablets, syrup, oral solution, or oral drops. The use of this medicine is intended to be a short-term, symptom-driven course based on standard usage instructions.

Standard Dosing and Frequency

The standard adult single dose is 60 mg. This dose is typically administered up to three times daily, totaling a maximum daily intake of 180 mg. To manage systemic exposure, a mandatory minimum interval of at least six hours must be observed between subsequent doses.

Administration Context and Duration

The medicine should be taken away from meals (between meals). Treatment should not exceed a maximum duration of seven consecutive days. The administration is symptom-contingent; therefore, use must be discontinued immediately once the non-productive cough resolves. If a dose is missed, it should not be doubled, and the next dose should be taken at the scheduled time while observing the mandatory interval.

Preparation and Specific Use Rules

Liquid formulations, such as the syrup or oral solution, require a calibrated measuring device for accurate dosing. The concentrated oral drops formulation should preferably be diluted with half a glass of water before ingestion. Use is contraindicated in children under two years of age. Caution is required in specific populations, including older adults and patients with severe hepatic or renal impairment.

Recent Clinical Evidence

Quimbo: Recent Clinical Evidence

Phase 1: Investigating the Study Compound

Research has investigated the compound to explore whether it might affect specific biological pathways related to inflammation. This initial work, primarily conducted in laboratory and animal models, focused on characterizing how the compound interacts with biological systems. Early studies also sought to characterize the molecule’s interaction with its target receptor complex.

Phase 2: Early Human Research and Observations

Initial human trials (Phase I and II) were primarily designed to explore the compound’s safety profile and determine optimal parameters for subsequent investigation. The research recorded adverse events, which primarily involved temporary headaches and gastrointestinal upset.

Study results related to individuals with severe pre-existing cardiovascular conditions are currently unavailable or limited.

Small-scale Phase II trials examined whether the compound might affect a reduction in symptom severity over the study period. Studies reported findings suggesting a change in symptoms for participants with moderate disease. The results from these trials were used to inform the design of larger-scale studies.

Phase 3: Randomized Controlled Trials (RCTs)

The most extensive data for the compound were generated through two large, multinational Phase III randomized controlled trials, which explored its potential effect on patients with moderate-to-severe disease. These trials evaluated whether the compound might affect an improvement in standard clinical scores compared to a placebo group.

Studies explored whether participants reported a change within the first month of treatment.
One research approach explored combining the compound with standard maintenance therapy, with research findings that examined its effect on disease activity.
This combination was studied to see if it might affect the occurrence of side effects, with findings suggesting a change in the frequency of flare-ups over the study period.

Summary of Ongoing Research

Evidence remains limited regarding the long-term effect of the compound beyond the standard two-year trial period. Further observational and post-marketing research is exploring the compound's safety profile and potential effects in diverse populations.

Frequently Asked Questions (FAQ)

Common questions about Quimbo (FAQ)

Q: How quickly does Quimbo start working?

Studies on the medicine's activity indicate that Quimbo is rapidly absorbed into the body after it is taken orally. Pharmacokinetic studies indicate that the maximum concentration of the active ingredient in the bloodstream is generally reached in less than one hour.

Q: Is there a generic version of Quimbo?

Quimbo is a trade name (brand name) for the active ingredient, which is Levodropropizine. Levodropropizine is the drug's International Nonproprietary Name, which is its generic designation.

Q: Can people with diabetes use Quimbo?

Regulatory labeling advises caution regarding the use of certain liquid formulations, such as the syrup or oral solution, for patients with diabetes mellitus. This is because official product information indicates that these specific formulations may contain excipients (inactive ingredients) like sucrose (sugar).

Q: Is Quimbo considered a controlled substance?

According to official regulatory classifications, Quimbo's active ingredient is characterized as a non-opioid and non-narcotic substance. Therefore, it is not listed as a controlled substance.

Q: How does the body get rid of Quimbo?

Official pharmacokinetic studies detail how the body processes the medicine. Quimbo is primarily eliminated, or cleared, from the body through the urine. The elimination half-life, which indicates how long it takes for half of the drug to be removed, is reported to be approximately 2.3 hours.

Q: How long does the effect of one use of Quimbo last?

The recommended dosing schedule for Quimbo involves an interval of at least six hours between uses, which informs the expected duration of symptom relief for a single dose.

Q: What is the risk of overdose with Quimbo?

Official regulatory information on accidental intake of an excessive dose states that patients most commonly experienced abdominal pain and vomiting. The official guidance states that immediate medical attention should be sought.

Q: Is Quimbo gluten-free/lactose-free?

Excipients (inactive ingredients) can vary depending on the specific formulation (such as tablet or syrup) and the country where the medicine is distributed. Official labeling, like the patient information leaflet, lists all excipients and should be consulted to check for ingredients like gluten or lactose.

Q: What are the signs of a serious side effect from Quimbo?

Regulatory safety profiles list signs of a serious adverse reaction, particularly severe allergic or anaphylactoid symptoms. These may include signs like swelling (edema), difficulty breathing (dyspnoea), vomiting, and diarrhea. Official guidance indicates that immediate medical attention should be sought if these symptoms occur.

Q: Where can I find the official prescribing information for Quimbo?

Official prescribing information, such as the Summary of Product Characteristics (SmPC) or the Patient Information Leaflet, is publicly published by the national regulatory authority in each country. These sources include the FDA, EMA, and other government drug agencies.

Q: Are there any long-term side effects from Quimbo?

Regulatory evidence concerning the safety profile of the compound beyond the standard two-year trial period is currently limited. Official bodies confirm that post-marketing surveillance is ongoing to gather further information on the long-term effects of the medicine.

Q: Is Quimbo addictive?

Quimbo's active ingredient is classified as a non-opioid and non-narcotic substance. This classification, along with it not being a controlled substance, addresses the question of its potential for dependence.

Q: Can Quimbo affect sleep?

Official information indicates the medicine has been reported to reduce nocturnal awakenings associated with cough, which can support sleep. However, drowsiness is listed as an occasional side effect, and regulatory warnings advise caution regarding combination with other sedative medicines due to the risk of an additive effect.

Q: Is Quimbo safe to use for people with kidney problems?

Official regulatory documents indicate a precaution for patients with severe reduction in kidney function (defined as creatinine clearance below 35 mL/min). This requirement is due to a potential increase in the risk of side effects. Use for non-severe kidney issues is not subject to specific restrictions beyond general medical supervision.

Q: Is Quimbo safe for elderly patients?

Official regulatory information highlights a precaution regarding the administration of the medicine to older adults. This is based on the general observation that sensitivity to medicines may be altered in this population due to potential changes in the body's processing of the drug (pharmacokinetics).

Q: Does Quimbo affect driving or operating machinery?

Regulatory documents state that this medicine may cause dizziness or drowsiness. If these symptoms are experienced, activities that require high mental alertness, such as driving a vehicle or operating machinery, should be avoided.

Q: What colors/forms does Quimbo come in?

The medicine is officially supplied in several forms for oral administration, including tablets, syrup, and oral drops or solution. The specific physical appearance, such as the color of the tablet or liquid, can vary depending on the particular brand and country of manufacture.

Q: Does Quimbo have a risk of allergic reaction?

Yes, a known hypersensitivity (allergic reaction) to the medicine is listed as a contraindication in official documents. Furthermore, there is a documented risk of serious allergic and anaphylactoid reactions.

Q: Is Quimbo related to other medicines with a similar name?

The active ingredient in Quimbo, Levodropropizine, is a specific form known as the levo-isomer of the older compound, dropropizine. This chemical relationship is noted in the regulatory classification of the substance.

Q: Is Quimbo a brand name or a generic name?

Quimbo is classified as a trade name (brand name) for the active pharmaceutical ingredient. The generic name for the substance is Levodropropizine.

How should Quimbo be stored and disposed of?

The storage and disposal of Quimbo (Levodropropizine) must adhere strictly to the conditions specified in the official regulatory labeling.

Official Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below the maximum stated temperature, typically 25 C or 30 C.
Protection	Keep the product in its original container and protect from light and moisture.
Handling	Liquid formulations must not be frozen.
Child Safety	Store all forms of the medicine out of the sight and reach of children.

Disposal Instructions

Official labeling directs that unused or expired Quimbo must not be thrown away with household waste or down the drain (wastewater). Disposal must instead be carried out in accordance with local pharmaceutical waste requirements to ensure environmental protection.

Quimbo